(HealthDay News) – A novel score based on four preoperative variables can predict the likelihood of type 2 diabetes remission following Roux-en-Y gastric bypass (RYGB) surgery, according to a study published online Sept. 13 in The Lancet Diabetes & Endocrinology.
Christopher D. Still, DO, from the Institute of Obesity in Danville, PA, and colleagues conducted a retrospective cohort study to predict the probability of diabetes remission after RYGB surgery, based on preoperative clinical criteria. A total of 2,300 patients who underwent RYGB surgery were included in the primary cohort. The authors examined 259 clinical variables in an effort to identify independent predictors of early remission (starting within the first two months after surgery) or late remission (starting more than two months after surgery) lasting ≥12 months.
Electronic medical records were available for 690 patients in the primary cohort. The researchers found that 63% of these participants achieved partial or complete remission. In the final model, insulin use, age, hemoglobin A1c concentration, and type of anti-diabetic drugs were included. A DiaRem score, ranging from 0–22, was developed, which gave the greatest weight to insulin use before surgery. Early remission was achieved by 88% of those who scored 0–2; 64% who scored 3–7; 23% who scored 8–12; 11% who scored 13–17; and 2% who scored 18–22. Similar results were seen in replication cohorts.
“The DiaRem score is a novel preoperative method to predict the probability of remission of type 2 diabetes after RYGB surgery,” the authors write.